The potential role of lonidamine (LND) i
β
Carmine M. Carapella; Marco G. Paggi; Fabio Cattani; Giovanni B. Ciottoli; Arist
π
Article
π
1989
π
Springer US
π
English
β 397 KB
Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with 'unconventional' modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This